PL2525796T3 - Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca - Google Patents

Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca

Info

Publication number
PL2525796T3
PL2525796T3 PL11701392.0T PL11701392T PL2525796T3 PL 2525796 T3 PL2525796 T3 PL 2525796T3 PL 11701392 T PL11701392 T PL 11701392T PL 2525796 T3 PL2525796 T3 PL 2525796T3
Authority
PL
Poland
Prior art keywords
quinuclidinones
hyperproliferative
autoimmune
treatment
aqueous solution
Prior art date
Application number
PL11701392.0T
Other languages
English (en)
Polish (pl)
Inventor
Styrbjörn Byström
Charlotta Liljebris
Ninus Caram-Lelham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2525796T3 publication Critical patent/PL2525796T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11701392.0T 2010-01-21 2011-01-21 Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca PL2525796T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29696410P 2010-01-21 2010-01-21
EP10151326 2010-01-21

Publications (1)

Publication Number Publication Date
PL2525796T3 true PL2525796T3 (pl) 2016-09-30

Family

ID=42212171

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11701392.0T PL2525796T3 (pl) 2010-01-21 2011-01-21 Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca

Country Status (22)

Country Link
US (1) US9061016B2 (en:Method)
EP (1) EP2525796B1 (en:Method)
JP (2) JP5845193B2 (en:Method)
KR (1) KR101727085B1 (en:Method)
CN (2) CN106963759B (en:Method)
AU (1) AU2011208681B2 (en:Method)
BR (1) BR112012017994B8 (en:Method)
CA (1) CA2786824C (en:Method)
CY (1) CY1117659T1 (en:Method)
DK (1) DK2525796T3 (en:Method)
ES (1) ES2578513T3 (en:Method)
HU (1) HUE028285T2 (en:Method)
IL (1) IL220318A (en:Method)
IN (1) IN2012DN05192A (en:Method)
PH (1) PH12012501402A1 (en:Method)
PL (1) PL2525796T3 (en:Method)
PT (1) PT2525796T (en:Method)
RU (1) RU2571566C2 (en:Method)
SG (1) SG182537A1 (en:Method)
SM (1) SMT201600189B (en:Method)
WO (1) WO2011089234A2 (en:Method)
ZA (1) ZA201204424B (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571566C2 (ru) * 2010-01-21 2015-12-20 Апреа Аб Способ и композиция
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
CN109280056A (zh) * 2017-07-21 2019-01-29 上海时莱生物技术有限公司 手性3-奎宁环酮类化合物、制备方法及用途
EP3762035A4 (en) * 2018-03-09 2022-03-02 Texas Tech University System COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER IN ALT
US20220087987A1 (en) * 2018-12-27 2022-03-24 National Cancer Center A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor
EP4031136A1 (en) 2019-09-18 2022-07-27 Aprea Therapeutics AB Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
WO2021158948A1 (en) * 2020-02-09 2021-08-12 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
CN111257458B (zh) * 2020-02-20 2022-07-22 北京鑫开元医药科技有限公司海南分公司 一种3-奎宁环酮盐酸盐的检测方法及应用
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3775418A (en) * 1970-07-15 1973-11-27 American Home Prod 3-((3-azaspiro(5,5)undecino)methyl)-3-quinuclidinol
US6921765B2 (en) 2000-09-20 2005-07-26 Aprea Ab 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
RU2226288C2 (ru) 2001-07-10 2004-03-27 ОПТИВА, Инк. Многослойное оптическое покрытие
DE60306896T2 (de) * 2002-02-21 2007-02-15 Aprea Ab Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
DK1605939T3 (da) 2003-03-24 2009-03-09 Aprea Ab Farmaceutisk anvendelse af 1-azabicyklo-2.2.2 oktaner og en fremgangsmåde til at teste forbindelser for den egenskab at aktivere inaktive WT P53
SE0400708D0 (sv) 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
JP2007269786A (ja) 2006-03-09 2007-10-18 Daiichi Sankyo Healthcare Co Ltd パンテチン含有経口液剤
JP2008001606A (ja) 2006-06-20 2008-01-10 Mitsubishi Pharma Corp ピラゾロン化合物を含有する水溶液剤
AU2006346318B2 (en) 2006-07-18 2011-02-10 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
AR065519A1 (es) 2007-03-01 2009-06-10 Vernalis Res Ltd Sales de adicion de acido, hidratos y polimorfos de la etil - amida del acido 5- (2,4- dihidroxi -5- isopropil - fenil )-4-(4- morfolin-4-il-metil - fenil ) - isoxasol-3- carboxilico y formulaciones que comprenden estas formas
RU2571566C2 (ru) * 2010-01-21 2015-12-20 Апреа Аб Способ и композиция

Also Published As

Publication number Publication date
US9061016B2 (en) 2015-06-23
AU2011208681B2 (en) 2014-10-23
JP6106228B2 (ja) 2017-03-29
KR20120123441A (ko) 2012-11-08
KR101727085B1 (ko) 2017-04-14
PH12012501402A1 (en) 2016-07-27
RU2012135698A (ru) 2014-02-27
ES2578513T3 (es) 2016-07-27
DK2525796T3 (en) 2016-07-04
BR112012017994B1 (pt) 2020-01-14
SMT201600189B (it) 2016-08-31
US20120289503A1 (en) 2012-11-15
JP2016020356A (ja) 2016-02-04
CA2786824C (en) 2018-04-10
HUE028285T2 (en) 2016-12-28
JP5845193B2 (ja) 2016-01-20
IN2012DN05192A (en:Method) 2015-10-23
WO2011089234A3 (en) 2011-10-06
CN106963759B (zh) 2020-07-07
AU2011208681A1 (en) 2012-07-05
CA2786824A1 (en) 2011-07-28
ZA201204424B (en) 2013-08-28
EP2525796A2 (en) 2012-11-28
RU2571566C2 (ru) 2015-12-20
PT2525796T (pt) 2016-07-11
BR112012017994B8 (pt) 2020-12-08
BR112012017994A2 (pt) 2016-05-03
WO2011089234A8 (en) 2012-09-07
AU2011208681A8 (en) 2013-01-31
CY1117659T1 (el) 2017-05-17
SG182537A1 (en) 2012-08-30
IL220318A (en) 2015-10-29
CN106963759A (zh) 2017-07-21
CN102781447B (zh) 2016-11-23
WO2011089234A2 (en) 2011-07-28
EP2525796B1 (en) 2016-03-30
CN102781447A (zh) 2012-11-14
JP2013518036A (ja) 2013-05-20

Similar Documents

Publication Publication Date Title
PL2525796T3 (pl) Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
ZA201209484B (en) Skin antiaging treatment
EP2645957A4 (en) ELIMINATION OF FAT BY NON-INVASIVE HYPERTHERMIC TREATMENT
PT2465423E (pt) Sistema para tratamento de tecido do músculo do coração
PL2575654T3 (pl) Implantowane urządzenie lecznicze, zamocowane lub połączone z kością
EP2605827A4 (en) NON-INVASIVE TREATMENT OF BRONCHOCONSTRICTION
PT2395993T (pt) Tratamento cutâneo
IL223289A0 (en) Treatment of type 2 diabetes
PL3260865T3 (pl) Sposób obróbki krwi, produktów krwiopochodnych i narządów
EP2638389A4 (en) TREATMENT OF EXTRACTION OF RENEWAL
GB201207543D0 (en) Treatment of transfusion blood
GB2482171B (en) Catalyst treatment
GB201002243D0 (en) Respiratory disease treatment
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
GB201002224D0 (en) Respiratory disease treatment
ZA201209298B (en) Hydroxyalkyl benzyl pyrazoles,and use thereof for the treatment of hyperproliferative and angiogenic diseases
PT2456445E (pt) Agente para o tratamento de condições da pele
ZA201304035B (en) Diarylpyridazinone derivatives,preparation thereof,and use thereof for the treatment of humans
ZA201005770B (en) The treatment of damaged skin
EP2531186A4 (en) TREATMENT OF HAIR DRESSES
GB2477743A9 (en) Respiratory disease treatment.
GB201001893D0 (en) Respiratory disease treatment
GB201001903D0 (en) Respiratory disease treatment
GB201001659D0 (en) Body treatment product